Ivacaftor
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Ivacaftor: From Cystic Fibrosis to Rheumatoid Arthritis
One-Sentence Summary
Ivacaftor is a CFTR potentiator whose proven use is in cystic fibrosis (CF), based on the mechanistic context described in this evidence pack. The TxGNN model predicts possible relevance to Rheumatoid Arthritis, with a prediction score of 96.97%, but this is currently supported by only 1 indirect clinical trial and 1 preclinical/basic-research publication — neither of which studied RA directly.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Cystic Fibrosis (CFTR potentiator; not derived from a Danish marketing authorisation, as none is on file) |
| Predicted New Indication | Rheumatoid Arthritis |
| TxGNN Prediction Score | 96.97% |
| Evidence Level | L4 |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on the information that is available, Ivacaftor is a CFTR (cystic fibrosis transmembrane conductance regulator) potentiator, and its efficacy in cystic fibrosis is well established in the broader literature referenced here.
The repurposing rationale in this pack describes a possible indirect link: in CF research, Ivacaftor has been observed to modulate neutrophil function and reduce inflammation (for example, decreased pancreatic ductal epithelial inflammation). Rheumatoid arthritis is an autoimmune, neutrophil-mediated joint inflammatory disease, so there is a theoretical connection via a CFTR–neutrophil–inflammation axis.
However, no direct evidence currently shows that CFTR modulators affect RA disease course. The high TxGNN score most likely reflects an indirect similarity between “neutrophil/inflammation” nodes in the knowledge graph, rather than a defined, RA-specific pharmacological mechanism. This prediction should be treated as a research hypothesis, not a validated repurposing signal.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT04970225 | N/A | Completed | 47 | Studied blood neutrophil function and phenotype in cystic fibrosis patients, including the impact of CFTR modulator treatment. Not designed around RA patients or RA endpoints — relevance grade C (mechanistic association only, via neutrophil biology; no direct relevance to the RA indication). |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28634110 | 2017 | Basic/Translational research (Tier 3) | Gastroenterology | Preclinical mouse models (NOD/ShiLtJ, BMP6-transduced, MRL/Mp) show that restoring CFTR activity in ducts reduces inflammation in pancreatic and salivary glands, in the context of Sjögren’s syndrome and autoimmune pancreatitis — not RA. |
Denmark Market Information
No marketing authorisations for Ivacaftor are currently on file for Denmark (market status: Not marketed; total authorisations: 0).
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.
Note: This evidence pack flags a blocking data gap — Danish label warnings/contraindications for Ivacaftor have not yet been retrieved, which prevents a full S1 safety pre-assessment.
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication (rheumatoid arthritis) is currently supported only by an indirect, low-relevance clinical trial (grade C, in CF patients, not RA patients) and a single preclinical/basic-research publication (Tier 3, not RA-focused). Evidence level is L4 with decision stage S1 (“Research Question”) — this is a mechanistic hypothesis, not clinical evidence, and does not yet justify further investment.
To proceed, the following is needed:
- Danish/EU SmPC warnings and contraindications for Ivacaftor (currently a Blocking data gap — required before any safety pre-assessment)
- Verified mechanism of action data via DrugBank API (currently a High-severity data gap)
- Drug-drug interaction (DDI) data (current query status: not found)
- RA-specific preclinical or clinical studies directly testing CFTR modulation in autoimmune/inflammatory arthritis models
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.